Phase 2 N=16 Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity
Congenital Hyperinsulinism
Primary: Area Under the Curve (AUC) Plasma Glucose — 26994.7; 32122.2 mg*min/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=505 Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26 — -0.92; -0.85 percentage of HbA1c
Phase 2 N=63 Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Blood Cancer · Multiple Myeloma
Primary: Event-free Survival (EFS) — 0; 24; 24 Participants
Phase 1 N=159 The Effects of Dopamine on Reward Processing
Major Depressive Disorder (MDD)
Primary: Effect on PST Reward Learning — 0.6271; 0.7575; 0.823; 0.7545 Effect size (Beta)
Phase 4 N=2,092 Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
Colon Cleansing
Primary: Distribution of the Overall Colon-cleansing Scale in Each Treatment Group. — 618; 243; 275; 423 Participants
N/A N=39 Comparison of Endotracheal Intubation Over the Aintree Via the I-gel and Laryngeal Mask Airway Supreme
Difficult Intubation
Primary: Time to Successful Tracheal Intubation — 197; 304 seconds
Phase 3 N=236 Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c — 7.93; 7.92; 6.78; 7.7 Percentage of glycosylated haemoglobin
Phase 2 N=100 A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Diabetes Mellitus, Type 2
Primary: Part A: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 2; 4 Participants
Phase 3 N=321 A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
Catecholamine-resistant Hypotension (CRH) · Distributive Shock · High Output Shock
Primary: An Increased MAP, Defined as Achievement of a Day 1 MAP at 3 Hours Following the Initiation of Study Drug, of ≥ 75 mmHg OR a 10 mmHg Increase in Baseline MAP — 114; 37…
Phase 4 N=165 Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular
Total Hip Arthroplasty
Primary: Maximum Postoperative Pain Score — 3.0; 4.0; 3.0 units on a scale — p=0.033
Phase 3 N=307 A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed by the Endpoint…
Phase 2 N=20 Study of Tocilizumab to Treat Polymyalgia Rheumatica
Polymyalgia Rheumatica (PMR)
Primary: Proportion of Patients in Disease Remission at Six Months From Trial Entry — 9; 0 Participants
Phase 3 N=87 NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Score — 24.3; 17.3 score on a scale — p=<0.0001
N/A N=142 Articulating Enseal Versus Ligasure Energy Devices
Task Performance
Primary: Raw Task Load Index (TLX) Score Assigned by Surgeons — 51.7; 32.5 units on a scale — p=0.0001
N/A N=12 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Duration of Local Control — 4.6 number of months to local failure